Alpine Immune Sciences, Inc. (NASDAQ:ALPN): Advancing Povetacicept, a Potentially Best-in-Class Dual BAFF/APRIL Inhibitor, Across Multiple Autoimmune Indications

Published on September 24, 2024

---